Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Lazard Asset Management LLC

Posted by on Mar 5th, 2023

Lazard Asset Management LLC decreased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) by 99.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,713 shares of the biotechnology company’s stock after selling 2,059,351 shares during the quarter. Lazard Asset Management LLC’s holdings in Sarepta Therapeutics were worth $188,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Moore Capital Management LP lifted its holdings in shares of Sarepta Therapeutics by 124.2% in the third quarter. Moore Capital Management LP now owns 180,060 shares of the biotechnology company’s stock valued at $19,904,000 after buying an additional 99,760 shares during the period. Penserra Capital Management LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter valued at $3,771,000. Nuveen Asset Management LLC lifted its holdings in shares of Sarepta Therapeutics by 2.3% during the third quarter. Nuveen Asset Management LLC now owns 326,869 shares of the biotechnology company’s stock valued at $36,132,000 after purchasing an additional 7,326 shares during the last quarter. Canada Pension Plan Investment Board lifted its holdings in shares of Sarepta Therapeutics by 40.9% during the third quarter. Canada Pension Plan Investment Board now owns 64,100 shares of the biotechnology company’s stock valued at $7,086,000 after purchasing an additional 18,600 shares during the last quarter. Finally, AXA S.A. lifted its holdings in shares of Sarepta Therapeutics by 0.4% during the third quarter. AXA S.A. now owns 98,105 shares of the biotechnology company’s stock valued at $10,845,000 after purchasing an additional 413 shares during the last quarter. Institutional investors and hedge funds own 87.31% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $155.61 on Friday. The company has a debt-to-equity ratio of 4.01, a current ratio of 4.13 and a quick ratio of 3.99. Sarepta Therapeutics, Inc. has a fifty-two week low of $61.28 and a fifty-two week high of $157.00. The stock’s 50-day moving average is $125.50 and its two-hundred day moving average is $117.73. The firm has a market cap of $13.69 billion, a P/E ratio of -19.38 and a beta of 0.97.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.04. The business had revenue of $258.43 million for the quarter, compared to analyst estimates of $250.51 million. Sarepta Therapeutics had a negative return on equity of 117.29% and a negative net margin of 75.40%. The firm’s revenue for the quarter was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.42) EPS. Analysts predict that Sarepta Therapeutics, Inc. will post -4.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. upped their target price on Sarepta Therapeutics from $153.00 to $206.00 and gave the company an “overweight” rating in a report on Friday. UBS Group raised Sarepta Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the company from $100.00 to $158.00 in a report on Friday, December 16th. SVB Leerink reissued an “outperform” rating and set a $160.00 price target on shares of Sarepta Therapeutics in a research report on Friday, January 20th. Royal Bank of Canada upped their price target on Sarepta Therapeutics from $195.00 to $226.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Oppenheimer upped their price target on Sarepta Therapeutics from $150.00 to $180.00 and gave the company an “outperform” rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.60.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Featured Stories

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.